Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Randomized controlled trial · Lancet · 2025. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
Chataway J, Williams T, Blackstone J et al.
Lancet · 2025
- PubMed ID
- 41045938
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.